These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 7882283)

  • 21. Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas.
    Raspollini MR; Amunni G; Villanucci A; Baroni G; Boddi V; Taddei GL
    J Chemother; 2003 Aug; 15(4):380-6. PubMed ID: 12962367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of p53 accumulation in epithelial ovarian carcinomas.
    Berker B; Dunder I; Ensari A; Cengiz SD
    Arch Gynecol Obstet; 2002 Aug; 266(4):205-9. PubMed ID: 12192480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.
    Nakayama K; Takebayashi Y; Nakayama S; Hata K; Fujiwaki R; Fukumoto M; Miyazaki K
    Cancer Lett; 2003 Mar; 192(2):227-35. PubMed ID: 12668287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.
    Shahin MS; Hughes JH; Sood AK; Buller RE
    Cancer; 2000 Nov; 89(9):2006-17. PubMed ID: 11064359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
    Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
    Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.
    Diamandis EP; Borgoño CA; Scorilas A; Yousef GM; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M
    Tumour Biol; 2003; 24(6):299-309. PubMed ID: 15004490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
    Ferrandina G; Fagotti A; Salerno MG; Natali PG; Mottolese M; Maneschi F; De Pasqua A; Benedetti-Panici P; Mancuso S; Scambia G
    Br J Cancer; 1999 Oct; 81(4):733-40. PubMed ID: 10574264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
    Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
    Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of p53 in epithelial ovarian cancer.
    Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
    Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
    Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
    Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.
    Sagarra RA; Andrade LA; Martinez EZ; Pinto GA; Syrjänen KJ; Derchain SF
    Int J Gynecol Cancer; 2002; 12(6):720-7. PubMed ID: 12445249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
    Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
    Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer.
    Anttila M; Kosma VM; Ji H; Wei-Ling X; Puolakka J; Juhola M; Saarikoski S; Syrjänen K
    J Clin Oncol; 1998 Aug; 16(8):2591-600. PubMed ID: 9704708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
    Kamiński K; Putowski L; Oleszczuk J
    Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
    Skirnisdottir I; Seidal T
    Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.
    Reles A; Schmider A; Press MF; Schönborn I; Friedmann W; Huber-Schumacher S; Strohmeyer T; Lichtenegger W
    J Cancer Res Clin Oncol; 1996; 122(8):489-94. PubMed ID: 8698749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.